Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne. The news flow around SGMT reflects its progress in clinical development, licensing collaborations, and capital markets activity.
Company announcements frequently highlight clinical trial milestones for its lead candidate denifanstat, including results from the Phase 2b FASCINATE-2 trial in MASH and Phase 3 acne data generated by its license partner in China. News items also cover secondary analyses using AI-based digital pathology and spatial computational histology to characterize fibrosis and treatment response in advanced MASH, as well as updates on a Phase 1 pharmacokinetic trial combining denifanstat with the thyroid hormone receptor beta agonist resmetirom.
Investors following SGMT news can also expect updates on Sagimet’s second oral FASN inhibitor, TVB-3567, which is in a Phase 1 first-in-human trial and is planned for acne development. Additional coverage includes regulatory interactions such as China’s National Medical Products Administration acceptance of a New Drug Application for denifanstat (ASC40) in acne, and Sagimet’s own disclosures about Breakthrough Therapy designation and end-of-Phase 2 interactions for denifanstat in MASH.
Beyond clinical and regulatory developments, Sagimet issues news on its license agreement with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program, participation in healthcare and liver disease conferences, and periodic financial and corporate updates reported via Form 8-K. This news page aggregates those press releases and related items so readers can track the evolution of Sagimet’s FASN inhibitor pipeline and key events affecting SGMT stock.
Sagimet Biosciences (Nasdaq: SGMT) has initiated dosing in a Phase 1 pharmacokinetic (PK) trial combining their oral FASN inhibitor denifanstat with THR-β agonist resmetirom. The trial will enroll approximately 40 healthy adult participants across 2 cohorts to evaluate drug interactions, safety, and tolerability.
The study aims to inform optimal dosing for a future Phase 2 combination trial in F4 MASH (metabolic dysfunction-associated steatohepatitis) patients. Topline data is expected in H1 2026. The combination therapy builds on promising preclinical data presented at EASL 2024, which demonstrated synergistic effects on liver disease markers when combining a FASN inhibitor with resmetirom.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will participate in a panel discussion at Fierce Biotech Week in Boston, MA from October 7-9, 2025. The company's Senior Vice President of Research and Development, Dr. Marie O'Farrell, will join a panel focused on AI/Machine Learning applications in biotechnology.
The presentation, scheduled for October 9, 2025, at 11:15 AM ET, will highlight Sagimet's use of AI-based digital pathology platforms in clinical trials, particularly for analyzing liver biopsies in metabolic dysfunction associated steatohepatitis (MASH) drug development.
Ascletis presented successful Phase III clinical trial results for denifanstat (ASC40), a first-in-class FASN inhibitor for acne treatment, at EADV Congress 2025. The trial, involving 480 patients with moderate to severe acne vulgaris, demonstrated that denifanstat met all primary, key secondary, and secondary efficacy endpoints.
Key achievements include 33.17% treatment success versus 14.58% for placebo, 57.38% reduction in total lesion count, and 63.45% reduction in inflammatory lesions. The drug showed a favorable safety profile, with TEAEs comparable to placebo (58.6% vs 56.3%). Ascletis plans to submit an NDA to China's NMPA following encouraging pre-NDA consultation feedback.
Sagimet Biosciences (Nasdaq: SGMT) announced positive Phase 3 trial results for denifanstat in treating moderate to severe acne, to be presented at the EADV Congress 2025. The trial, conducted by partner Ascletis in China, met all primary and secondary endpoints with 480 patients receiving either denifanstat 50mg or placebo daily for 12 weeks.
Key results include an 18.6% placebo-adjusted increase in treatment success rate, 22.0% reduction in total lesions, and 20.2% reduction in inflammatory lesions. Additionally, Sagimet has initiated a Phase 1 trial for TVB-3567, a second FASN inhibitor, for acne treatment.
Sagimet Biosciences (Nasdaq: SGMT) announced its participation in the 9th Annual MASH Drug Development Summit from September 29-October 1, 2025, in Boston. The company will deliver two oral presentations and participate in a panel discussion focused on their FASN inhibitor denifanstat.
Dr. Marie O'Farrell will present findings on denifanstat's mechanism of action in MASH, including combination treatments with semaglutide and resmetirom, highlighting results from the Phase 2b FASCINATE-2 study. Dr. Wen-Wei Tsai will discuss the application of AI-based digital pathology in evaluating denifanstat's anti-fibrotic effects in MASH patients with F3 fibrosis.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and fibrotic pathways, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3, featuring a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. A webcast of the Cantor presentation will be available on Sagimet's website for 90 days after the event.
Sagimet Biosciences (NASDAQ:SGMT) reported significant progress in Q2 2025, highlighted by positive Phase 3 trial results for denifanstat in acne treatment through its partner Ascletis in China. The trial met all primary endpoints, showing 33.2% treatment success vs. 14.6% for placebo.
The company initiated a Phase 1 trial for TVB-3567, another FASN inhibitor for acne treatment in the U.S. Additionally, Sagimet plans to start a Phase 1 trial evaluating denifanstat combined with resmetirom for MASH treatment in 2H 2025. As of June 30, 2025, the company reported $135.5 million in cash and equivalents, with a net loss of $10.4 million for Q2 2025.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic pathways, will participate in the Canaccord Genuity 45th Annual Growth Conference.
The company's management will engage in a fireside chat on August 13, 2025, at 2 p.m. EDT in Boston, MA. Investors can access the webcast through Sagimet's website, with a replay available for 90 days after the event.